IOVA analyst estimates
Iovance (IOVA) analyst ratings, the average price target and its range, and every firm's latest call.
IOVA analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 13, 2026 | Barclays | Iovance Biotherapeutics price target raised to $18 from $15 at Barclays | $18.00 |
| Oct 8, 2026 | Robert W. Baird | Iovance Biotherapeutics price target raised to $11 from $6 at Baird | $11.00 |
| Sep 30, 2026 | Wells Fargo | Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Wells Fargo | $18.00 |
| Sep 29, 2026 | Jefferies | Iovanace Biotherapeutics (IOVA) PT Raised to $16 at TD Cowen Following Raised Outlook | $16.00 |
| Sep 29, 2026 | H.C. Wainwright | Iovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright | $20.00 |
| Sep 24, 2026 | Goldman Sachs | Iovance Biotherapeutics resumed with a Buy at Goldman Sachs | $15.00 |
| Sep 17, 2026 | Barclays | Iovance Biotherapeutics price target raised to $15 from $13 at Barclays | $15.00 |
| Aug 20, 2026 | UBS | Iovance Biotherapeutics price target raised to $7 from $4 at UBS | $7.00 |
| Aug 18, 2026 | Mizuho Securities | Iovance Biotherapeutics price target raised to $11 from $10 at Mizuho | $11.00 |
| Aug 7, 2026 | Barclays | Iovance Biotherapeutics price target raised to $13 from $11 at Barclays | $13.00 |
| Aug 7, 2026 | Robert W. Baird | Iovance Biotherapeutics price target raised to $6 from $4 at Baird | $6.00 |
| Jun 1, 2026 | National Bank | Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens | $5.00 |
| Jun 1, 2026 | Wells Fargo | Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens | $5.00 |
| Feb 5, 2026 | Goldman Sachs | Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs | $2.00 |
| May 16, 2025 | UBS | Iovance Biotherapeutics downgraded to Neutral from Buy at UBS | $2.00 |
- 10 firms rate IOVA: 8 buy, 2 hold, 0 sell.
- The average price target is $13.44 from 9 analysts, from $5.00 to $20.00.
Updated 2026-11-02 17:51 UTC